Please assess the completion status of the following clinical trial:

Trial Title: PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/Guardian/Participant is willing and able to give informed consent/assent~* Physician-diagnosed asthma that is inadequately controlled as per view of doctor (for example, history of at least two emergency visits to GP or hospital over the previous year, frequent use of blue inhaler (three times or more per week))~* Aged 5-11 years (inclusive)~* Children who are already on at least 400 micrograms per day inhaled beclomethasone or equivalent and hence ready to be prescribed inhaled long-acting beta2 agonists and/or other add-on medication or are already on inhaled long-acting beta2 agonists and/or other add-on medication~Exclusion Criteria:~* Parent/Guardian/Participant is unwilling or unable to give informed consent/assent~* Known contraindication to montelukast or salmeterol~* Other known significant airway or lung disease (e.g. chronic lung disease of prematurity, cystic fibrosis or congenital airway abnormalities) or other co-existing serious disease such as congenital cardiac disease~* Poor inhaler technique and/or history of poor adherence on checking following standard procedure at the clinic~* Participating in another clinical trial (other than observational trials and registries) concurrently or within 30 days prior to screening for entry into this study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Personalised Medicine (Type: EXPERIMENTAL): Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
- Standard Care (Type: NO_INTERVENTION): Standard of care (Standard Care will be prescribed controller medication based on guidelines)

Based on this trial design, predict the completion outcome and termination type (if applicable).